Press Releases

02 May 2018

In memory of Eugenio Aringhieri, CEO Dompé, member of the EBE Board of Directors

It is with great sadness that we received the news of the sudden and untimely passing of our Board member Eugenio Aringhieri, CEO Dompé, on 1 May 2018. Eugenio Aringhieri has contributed to th...

Read more
23 Mar 2018

Statement in response to the EU Council ratifying the Brexit transition deal

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today respond...

Read more
05 Dec 2017

Escher Study Identifies Hurdles to ATMP Development in Europe

First results of a study into factors associated with successful development of Advanced Therapy Medicinal Products (ATMPs) were reported today by Utrecht University at European Biopharmaceuti...

Read more
23 Nov 2017

EBE and EFPIA call for policy support to make personalised medicine a reality for patients

Ahead of the first congress of the European Alliance for Personalised Medicine (EAPM) “Personalising your health: A global imperative!” on 27-30 November 2017 in Belfast, the Joint EBE-EFPIA Perso...

Read more
10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
27 Sep 2017

ARM, EBE, EFPIA and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe

The Alliance for Regenerative Medicine (ARM), the European Biopharmaceutical Enterprises (EBE), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe....

Read more
29 Jun 2017

EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR

The launch of the European Commission’s Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting this phenomenon, by proposing concrete and innovative solutions to benefit patients worldwide....

Read more
26 Apr 2017

Intellectual Property: the key to innovation and survival for small and medium-sized biopharma companies

Today is World Intellectual Property day, an opportunity to reflect on the relevance of intellectual property rights to society where invention and innovation is valued for the greater benefit of all. ...

Read more
09 Mar 2017

EBE, EFPIA and IFPMA Have Today Launched a Position Paper Entitled “Considerations for Physicians on Switching Decisions Regarding Biosimilars”

Switching describes a physician's decision to exchange one product that a patient receives for another. With the introduction of biosimilars, physicians may be encouraged to switch patients from an original biologic (reference product) to any of its biosimilars (or vice versa) in order to reduce costs. ...

Read more
16 Feb 2017

EBE and EFPIA support ARM Initiative on Hospital Exemptions and Call for Increased Transparency on All Advanced Cell, Gene and Tissue Therapies

The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) today express their support for key aspects of the “Positio...

Read more
1 2 3 4